Tech Company Financing Transactions
Protemix Funding Round
On 4/4/2007, Protemix announced $14.5 million in Series A investment from NovaQuest and Novartis BioVenture Fund.
Transaction Overview
Company Name
Announced On
4/4/2007
Transaction Type
Venture Equity
Amount
$14,500,000
Round
Series A
Investors
NovaQuest (Lead Investor)
Novartis BioVenture Fund (Lead Investor) (Reinhard Ambros)
Proceeds Purpose
Proceeds from the financing will be used to advance the clinical development of Protemix's lead product, PX811019, as a potential treatment for diabetic heart failure, as well as the continued preclinical development of PX811013, a novel form of the glycoprotein hormone adiponectin, and other earlier stage programs in the company's pipeline.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
4401 Eastgate Mall
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Protemix is a privately held biopharmaceutical company that discovers, develops and commercializes novel drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders, and their complications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Larry Ellingson
Chief Operating Officer
David Pool
Browse more venture capital transactions:
Prev: 4/4/2007: SustainLane venture capital transaction
Next: 4/4/2007: Surface Logix venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs